Orbital hemorrhage and compressive optic neuropathy in patients with midfacial fractures receiving low-molecular weight heparin therapy.
While the implementation of deep vein thrombosis (DVT) prophylaxis in the hospital setting is a major concern, the use of antithrombotic agents is fraught with a variety of hemorrhagic complications. Due to increasing reports of adverse reactions to unfractionated heparin (UFH), several manufacturers have initiated product recalls. As a result, the use of low-molecular weight heparins (LMWHs) such as enoxaparin has risen substantially. In this paper, 2 orbital hemorrhagic complications in patients receiving enoxaparin therapy will be presented. The incidence of DVT in the OMS patient, recent prophylactic strategies, and their effectiveness will be reviewed.
Jamal
Basem T
BT
Oral and Maxillofacial Surgery Department, Thomas Jefferson University Hospital, Philadelphia, PA, USA. basem_jamal@yahoo.com
Diecidue
Robert J
RJ
Taub
Daniel
D
Champion
Allen
A
Bilyk
Jurij R
JR
D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D017984:Enoxaparin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D008440:Maxillary Fractures / Q000150:complications; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000209:etiology*; D009917:Orbital Fractures / Q000150:complications*; D019315:Retrobulbar Hemorrhage / Q000209:etiology* / Q000601:surgery; D015051:Zygomatic Fractures / Q000150:complications
D000925:Anticoagulants; D017984:Enoxaparin